Related Experiment Video
Updated: Jun 4, 2026

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
Published on: November 24, 2021
Advances in the analysis of non-allowed pharmacologically active substances in cosmetic products
Manuela Pellegrini1, Emilia Marchei, Roberta Pacifici
1Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, V.le Regina Elena 299, 00161 Rome, Italy.
Abstract:
The state-of-the art analysis of non-allowed pharmacologically active substances in cosmetic products is here presented and a new methodology developed for this type of analysis is proposed. Cosmetic products released on the market should not cause damage to human health when applied under normal conditions of use. With respect to this condition, the definition of "cosmetic product" is reported according to the international and region specific regulatory requirements for the manufacturing and marketing and that of non-allowed substances with particular reference to pharmacologically active substances, with therapeutic indication. The existing methodologies for the analysis of non-allowed products in cosmetic preparations generally include some sort of sample treatment and/or extraction before the analytical step, which always include a separation by liquid chromatography (LC) at ambient temperature followed by detection with ultraviolet spectrophotometric detection or mass spectrometry. A systematic high throughput analysis of non-allowed pharmacologically active substances is finally proposed together with the results of such an analysis performed in the "Drug abuse and doping" Unit of the National Institute of Health in Rome.
Related Concept Videos
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
Drug Regulation
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
FDA Approved Drugs: Changes to Approved Drugs
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
